 |
Investor Relations
|
Vitro Appoints Prominent Denver Investment Banker to its Board of Directors
February 23, 2010
Golden, Colorado—February 23, 2010—Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, announced the appointment of Richard Huebner to its Board of Directors. Mr. Huebner is a Senior Managing Partner of GVC Capital (formerly Bathgate Capital) a Denver-based investment bank focused on microcap companies. Mr. Huebner has an extensive, 30-year background in the securities industry. He received a BA in Economics and Business Administration from Hastings College and a J.D. from the University of Nebraska. He was previously General Counsel for Hanifen, Imhoff, Inc. from 1984 to 1995 where he served in numerous positions. Following the sale of Hanifen, Imhoff to Fiserv, Inc in 1997, he continued with that firm. He joined Bathgate Capital in 2001. Mr. Huebner joins existing Board members, Dr. Jim Musick, Vitro’s President and CEO, who directed the establishment of the Company in its present form and Erik Van Horn, BSChE who is presently employed by a leading biotechnology firm as a specialist in the manufacture of human biotherapeutics.
Mr. Huebner stated, “I am pleased to be joining Vitro’s Board at this time and look forward to providing my expertise to assist the Company in achieving its goals of expanded distribution and development of its commercially available products supporting stem cell research and drug discovery. Also, it is clear that stem cell technology has significant potential for the development of novel regenerative medicine advances and I look forward to assisting Vitro to gain entrance into therapeutic markets. Through my involvement in capital structure and fund raising of a myriad of companies including small biotech firms, I believe that my involvement will be beneficial to Vitro and its shareholders.”
About Vitro Diagnostics, Inc.
Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCBB: VODG; HYPERLINK "http://www.vitrobiopharma.com" http://www.vitrobiopharma.com), owns US patents for production of a fertility drug, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes. Vitro’s mission is “Harnessing the Power of Cells™” for the advancement of regenerative medicine to its full potential. Vitro also owns pending US patents for stem cell therapy of cancer, generation of pluripotent stem cells and is continuously developing patentable cell lines and technologies. Vitro operates within a new high tech and regulatory compliant manufacturing, R&D and corporate facility in Golden, Colorado. Vitro manufactures and sells “Tools for Stem Cell and Drug Development™”, including human mesenchymal stem cells and derivatives, optimized media for sustained self-renewal, lineage-specific differentiation and products supporting induced pluripotent stem cell and cancer research.
Safe Harbor Statement
Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Dr. James Musick
Chief Executive Officer
Vitro Diagnostics, Inc.
(303) 999-2130
E-mail: jim@vitrodiag.com
Source: Vitro Diagnostics, Inc.